Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT06743334

Secondary Databased Post-marketing Surveillance Study of BNT162b2

Sponsor: Pfizer

View on ClinicalTrials.gov

Summary

This study is to assess the post-marketing safety of BNT162b2 products using nationwide population-based database in Republic of Korea.

Key Details

Gender

All

Age Range

6 Months - Any

Study Type

OBSERVATIONAL

Enrollment

14302529

Start Date

2025-04-23

Completion Date

2025-05-28

Last Updated

2026-07-10

Healthy Volunteers

No

Interventions

BIOLOGICAL

Tozinameran (BNT162b2)

1. 12 years or older * Primary series: 2 doses, 30 μg each, administered 21 days apart * Booster shot (dose 3): 1 dose, 30 μg after ≥ 6 months from the second shot 2. 5 to 11 years of age * Primary series: 2 doses, 10 μg each, administered 21 days apart * Booster shot (dose 3): 1 dose, 10 μg after ≥ 6 months from the second shot 3. 6 months to 4 years of age * Primary series: 3 doses (2 doses of 3 μg each, administered 21 days apart, followed by 1 dose after ≥8 weeks)

BIOLOGICAL

Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1)

1\. 12 years or older \- Single booster dose, 15/15 μg, administered after ≥3 months after primary series

BIOLOGICAL

Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)

1\. 12 years or older \- Single booster dose, 15/15 μg administered after ≥3 months after primary series

Locations (1)

Pfizer

Seoul, South Korea